Cone-rod dystrophy 5

disease
On this page

Also known as cone-rod dystrophy caused by mutation in PITPNM3cone-rod dystrophy type 5CORD5PITPNM3 cone-rod dystrophy

Summary

Cone-rod dystrophy 5 (MONDO:0010969) is a disease caused by PITPNM3 (GenCC Strong), with 1 cohort gene.

At a glance

  • Causal gene: PITPNM3 (GenCC Strong)
  • Cohort genes: 1
  • ClinVar variants: 162

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical namecone-rod dystrophy 5
Mondo IDMONDO:0010969
MeSHC563415
OMIM600977
DOIDDOID:0111010
UMLSC1832976
MedGen322083
GARD0010655
Is cancer (heuristic)no

Also known as: cone-rod dystrophy 5 · cone-rod dystrophy caused by mutation in PITPNM3 · cone-rod dystrophy type 5 · CORD5 · PITPNM3 cone-rod dystrophy

Data availability: 162 ClinVar variants · 2 GenCC gene-disease records.

Disease family

Classification path: disease › human disease › disease by body system or component › nervous system disorderretinal disorderretinal degenerationinherited retinal dystrophycone-rod dystrophycone-rod dystrophy 5

Related subtypes (27): cone-rod dystrophy 2, macular degeneration, X-linked atrophic, cone-rod dystrophy 1, cone-rod dystrophy 6, cone dystrophy 3, cone-rod dystrophy 7, cone-rod dystrophy 3, Leber congenital amaurosis 4, cone-rod dystrophy 8, Newfoundland cone-rod dystrophy, cone-rod dystrophy 13, cone-rod dystrophy 10, cone-rod dystrophy 11, retinal cone dystrophy 4, cone-rod dystrophy 12, cone-rod dystrophy 9, cone-rod dystrophy 15, cone-rod dystrophy 16, cone-rod dystrophy 17, cone-rod dystrophy 18, cone-rod dystrophy 19, cone-rod dystrophy 20, cone-rod dystrophy 21, X-linked cone-rod dystrophy, cone-rod dystrophy 22, cone-rod dystrophy 14, cone-rod dystrophy 24

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

162 retrieved; paginated sample, class counts are floors:

75 uncertain significance, 48 benign, 25 conflicting classifications of pathogenicity, 10 benign/likely benign, 4 likely benign

ClinVarVariant (HGVS)GeneClassificationReview
167471NM_031220.4(PITPNM3):c.1124C>T (p.Pro375Leu)PITPNM3Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
194272NM_031220.4(PITPNM3):c.1688C>T (p.Thr563Met)PITPNM3Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
194895NM_031220.4(PITPNM3):c.2355G>A (p.Pro785=)PITPNM3Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
198270NM_031220.4(PITPNM3):c.507C>A (p.Phe169Leu)PITPNM3Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
199174NM_031220.4(PITPNM3):c.987G>A (p.Leu329=)PITPNM3Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
1994NM_031220.4(PITPNM3):c.1878G>C (p.Gln626His)PITPNM3Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
324747NM_031220.4(PITPNM3):c.1899G>A (p.Thr633=)PITPNM3Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
324748NM_031220.4(PITPNM3):c.1854G>A (p.Glu618=)PITPNM3Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
324751NM_031220.4(PITPNM3):c.1538G>A (p.Arg513His)PITPNM3Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
324755NM_031220.4(PITPNM3):c.1019G>A (p.Arg340Gln)PITPNM3Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
324757NM_031220.4(PITPNM3):c.914C>T (p.Ala305Val)PITPNM3Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
324760NM_031220.4(PITPNM3):c.747G>A (p.Lys249=)PITPNM3Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
324762NM_031220.4(PITPNM3):c.456C>A (p.Ala152=)PITPNM3Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
324763NM_031220.4(PITPNM3):c.368G>A (p.Arg123His)PITPNM3Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
324769NM_031220.4(PITPNM3):c.195C>T (p.Ile65=)PITPNM3Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
324772NM_031220.4(PITPNM3):c.22+15G>CPITPNM3Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
838018NM_031220.4(PITPNM3):c.2190G>A (p.Thr730=)PITPNM3Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
839720NM_031220.4(PITPNM3):c.287G>A (p.Arg96Gln)PITPNM3Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
888971NM_031220.4(PITPNM3):c.1018C>T (p.Arg340Trp)PITPNM3Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
889652NM_031220.4(PITPNM3):c.853G>A (p.Asp285Asn)PITPNM3Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
889654NM_031220.4(PITPNM3):c.651C>T (p.Ala217=)PITPNM3Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
890612NM_031220.4(PITPNM3):c.1942C>T (p.Pro648Ser)PITPNM3Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
891165NM_031220.4(PITPNM3):c.1608C>T (p.Pro536=)PITPNM3Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
892364NM_031220.4(PITPNM3):c.1377C>T (p.Ser459=)PITPNM3Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
892365NM_031220.4(PITPNM3):c.1314C>T (p.Asp438=)PITPNM3Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
888912NM_031220.4(PITPNM3):c.*54G>ALOC130060086Uncertain significancecriteria provided, single submitter
1032920NM_031220.4(PITPNM3):c.2305C>T (p.Arg769Trp)PITPNM3Uncertain significancecriteria provided, single submitter
1305959NM_031220.4(PITPNM3):c.2166G>C (p.Gln722His)PITPNM3Uncertain significancecriteria provided, multiple submitters, no conflicts
324652NM_031220.4(PITPNM3):c.*4047C>TPITPNM3Uncertain significancecriteria provided, single submitter
324655NM_031220.4(PITPNM3):c.*3707G>APITPNM3Uncertain significancecriteria provided, single submitter

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 3 · Orphanet: 1 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

GenCC gene–disease validity (cohort genes)

the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.

GeneClassificationInheritanceDiseaseRecords
PITPNM3StrongAutosomal dominantcone-rod dystrophy 53

Orphanet rare-disease linkage (cohort genes)

GeneOrphanet IDRare disease
PITPNM3Orphanet:1872Cone rod dystrophy

Cohort genes → proteins

1 cohort genes, 1 distinct canonical proteins.

Evidence partition

SubsetGenes
multi_evidence1

Cohort genes (full)

SymbolHGNCEnsemblUniProtNameEvidence
PITPNM3HGNC:21043ENSG00000091622Q9BZ71Membrane-associated phosphatidylinositol transfer protein 3gencc,clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

SymbolProtein nameFunction (lead sentence)
PITPNM3Membrane-associated phosphatidylinositol transfer protein 3Catalyzes the transfer of phosphatidylinositol and phosphatidylcholine between membranes (in vitro).

Protein-family classification

Druggable: 0 · Difficult: 0 · Unknown: 1 · Druggable fraction: 0.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

FamilyGenesFoldFDR
Other/Unknown11.8×0.558

Per-gene assignment

SymbolFamilyDruggable?ECInterPro (top 3)
PITPNM3Other/UnknownnoPI_transfer, DDHD_dom, HAD_sf

Expression context

Cohort genes with no expression data: 0.

1 cohort gene are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

BucketGenes
narrow (1-5 tissues)0
moderate (6-20)0
broad (>20)1
unknown0

Top tissues across cohort

TissueCohort genes
Brodmann (1909) area 231
endothelial cell1
pancreatic ductal cell1

Per-gene tissue summary (top 30)

SymbolBgee breadthFANTOM5 breadthSCXATop tissues
PITPNM3222broadmarkerpancreatic ductal cell, endothelial cell, Brodmann (1909) area 23

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

SymbolInteractor count
PITPNM3817

Structural data

PDB: 1 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

SymbolUniProtPDB entries
PITPNM3Q9BZ711

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 1. Enrichment computed across 1 evidence-associated genes (1 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

PathwayCohort genesFoldFDRSample cohort genes
Synthesis of PI12284.0×4e-04PITPNM3

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO termCohort genesFoldFDRSample cohort genes
phosphatidylinositol biosynthetic process1366.4×0.003PITPNM3

Therapeutics

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 1

Druggability breadth: 0 of 1 evidence-associated genes (0%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

SymbolMoleculesMax phase
PITPNM300

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Pharmacogenomics

Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

TierDefinitionGenesSymbols
AApproved (phase 4 drug)0
BPhased (≥1) drug, not yet approved0
CDruggable family + PDB, no drug0
DDruggable family + AlphaFold only, no drug0
EDifficult family or no structure, no drug1PITPNM3

Undrugged target profiles

1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

SymbolChEMBL assaysDrugged partners (top 3)
PITPNM30

Clinical trials & evidence

Clinical trials

Clinical trials: 0.